A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TQA3038 Injection in Healthy Adult Subjects.
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics.
In the single ascending dose (SAD) part, healthy adult subjects will receive one dose of TQA3038 or placebo, administered subcutaneously (SC).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Dong Liu, Doctor
- Phone Number: +86 13507183749
- Email: ld_2069@163.com
Study Contact Backup
- Name: ZheLong Liu, Doctor
- Phone Number: +86 13986235028
- Email: liuzhelong@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 40030
- Recruiting
- Tongji Hospital
-
Contact:
- Dong Liu, Doctor
- Phone Number: +8613507183749
- Email: ld_2069@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female age 18~60 years.
- Body mass index (BMI) 19 - 26 kg/m^2.
Exclusion Criteria:
- Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation;
- History or evidence of drug or alcohol abuse;
- History of intolerance to SC injection;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TQA3038 injection
One dose of TQA3038 injection in Day 1.
|
TQA3038 is an injection.
|
|
Placebo Comparator: TQA3038 injection matching placebo
One dose of TQA3038 injection matching placebo in Day 1.
|
Placebo injection contains no active substance.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to 85 days.
|
Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
|
Up to 85 days.
|
|
Number of subjects with clinically significant abnormalities
Time Frame: Up to 85 days.
|
Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.
|
Up to 85 days.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Plasma Concentration (Cmax)
Time Frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
Maximum concentration of TQA3038 and its metabolite in plasma
|
Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
|
Time to Reach Maximum Plasma Concentration (Tmax)
Time Frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
Time to reach Cmax of TQA3038 and its metabolite in plasma
|
Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
|
Area Under the Plasma Concentration Versus Time Curve (AUC)
Time Frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
Area under the curve of TQA3038 and its metabolite from time 0 to last measurable time
|
Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
|
Apparent Terminal Elimination Half-life (T1/2)
Time Frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
Apparent Elimination Half-life (T1/2) of TQA3038 in Plasma
|
Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
|
Apparent Plasma Clearance (CL/F)
Time Frame: Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
Apparent Plasma Clearance (CL/F) of TQA3038 in Plasma
|
Predose on Day 1 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 48 hours postdose
|
|
Fraction eliminated in the urine
Time Frame: Predose, 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 48 hours and 168 hours after dose on Day 1.
|
Apparent Plasma Clearance (CL/F) of TQA3038 in Plasma
|
Predose, 0-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 48 hours and 168 hours after dose on Day 1.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Hepatitis, Chronic
- Hepatitis
- Chronic Disease
- Hepatitis B
- Hepatitis B, Chronic
Other Study ID Numbers
Other Study ID Numbers
- TQA3038-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.